Seoul, South Korea

Soo Jin Oh

USPTO Granted Patents = 3 

Average Co-Inventor Count = 5.7

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2014-2017

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovations of Soo Jin Oh

Introduction

Soo Jin Oh is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific calcium channels. With a total of 3 patents to his name, his work is paving the way for advancements in medical treatments.

Latest Patents

Soo Jin Oh's latest patents include innovative compounds that serve as chloride channel blocking agents. One of his notable inventions is a novel compound designed to function as a calcium-dependent chloride channel blocking agent. Additionally, he has developed a phenoxypropanol derivative, which is represented by a specific chemical structure. This derivative can be utilized for blocking T-type calcium channels and/or TREK channels, offering potential treatments for associated diseases.

Career Highlights

Soo Jin Oh is affiliated with the Korea Institute of Science and Technology, where he conducts his research and development. His work focuses on creating pharmaceutical compositions that can effectively address various medical conditions. His dedication to innovation in the pharmaceutical field has garnered attention and respect from his peers.

Collaborations

Soo Jin Oh collaborates with esteemed colleagues, including ChangJoon Justin Lee and Eun Mi Hwang. Their combined expertise contributes to the advancement of research and development in their respective fields.

Conclusion

Soo Jin Oh's contributions to the field of pharmaceuticals through his innovative patents highlight his role as a leading inventor. His work not only showcases his expertise but also holds promise for future medical advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…